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Background: Hepatitis C virus (HCV) and Schistosoma mansoni are major causes of chronic liver disease (CLD) in
which immune alteration is common. Recent studies suggested that certain platelets and lymphocytes activation
markers may have an impact on progression of CLD. This study aimed to evaluate the potential of platelets and
lymphocytes activation molecules expression on the pathogenesis of CLD in distinct or concomitant chronic HCV
and schistosomiasis mansoni infections.
Methods: The study populations were divided into group-I: patients with chronic schistosomiasis mansoni, group-II:
HCV patients without cirrhosis, group-III: patients with combined liver diseases without cirrhosis, group-IV: patients
with chronic HCV and liver cirrhosis and group-V: Age and sex matched healthy individuals as normal controls. All
groups were subjected to full clinical evaluation, ELISA anti-HCV antibodies screening, parasitological examination
for diagnosing S. mansoni and flow cytometry for lymphocyte (CD3, CD4, CD8, CD19, CD22, & CD56) and platelets
activation (CD41, CD42 & CD62P (P- selectins)) markers.
Results: The platelet count was significantly decreased in HCV and/or S. mansoni patients. The total T-lymphocytes
and T-helper cells were significantly reduced, while T-cytotoxics were increased. The patients possessed a
significantly higher platelets activation marker; CD62P (P-selectins) and higher mean fluorescent intensity (MFI)
positivity. There were considerable correlations between platelets count and both of CD62P and MFI.
Conclusion: Our Findings suggest an increased expression of certain platelets and lymphocytes activation markers
in chronic HCV and S. mansoni induced CLD that may have a role in disease progression.
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It is becoming esteemed that platelets activity extends be-
yond ensuring the integrity of the vasculature to comprise
defense mechanisms against invading pathogens [1].
Despite their small size and a nucleate status, platelets
have diverse roles in vascular biology. In some perspec-
tives, platelet immune functions are protective, whereas in
others platelets contribute to adverse inflammatory out-
comes [2]. Platelet dysfunctions are commonly associated
with CLD and the paradigmal platelet function test has
been reported to be abnormal in 2.5–42% of cirrhotic* Correspondence: mm.kamel@yahoo.com
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unless otherwise stated.patients [3]. Platelets are activated in liver cirrhosis,
hepatocellular carcinoma, schistosomiasis and HCV
infections [4]. Thrombocytopenia is frequently found in
patients with CLD and cirrhosis. The precise mechanism
of thrombocytopenia is unknown; however, several theories
have been proposed including decreased thrombopoietin
production and accelerated platelet destruction caused by
hypersplenism [5].
It is noteworthy that activated platelets have anti-
inflammatory properties related to the interaction between
CD40L and CD40 and exert a hitherto undescribed im-
munoregulatory action by enhancing IL-10 production
and inhibiting TNF-α production by monocytes [6]. In the
complex cytokine network, IFN-ɣ, IL-12, IL-4, and IL-10
play an important role in responses to viral infections bytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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anism of S. mansoni infection tightly acorrelates with high
IL-13 and low IFN-γ/IL-10 [8]. Platelet membrane has a
large number of glycoproteins that are essential for their
normal functioning. Some glycoproteins are present in the
resting state as well as after stimulation e.g. CD41, CD42
and CD61. Fibrinogen receptors, CD62p (P-selectin) and
CD63 are neoepitopes that appear only on the surface of
activated platelets. CD36 induces platelets activation with
CD62 expression and their adhesion on leukocytes due to
CD62 and CD162 interactions [9]. P-selectins mediate
interaction between endothelium, platelets and leucocytes
by phosphorylation of histidine residues of the molecule
[6]. Of the three known E, L and P-selectins, P-selectins
were found to have a critical role in the progression of
CLD caused by schistosome parasites. P-selectin is widely
thought to promote inflammatory reactions by facilitating
leukocyte recruitment. However, it was surprisingly found
that mice with targeted deletion of the P-selectin gene
(PsKO mice) developed unpolarized type 1/type 2 cyto-
kine reactions and vigorously enhanced liver pathology
following infection with the type 2-promoting S. mansoni
[10]. The ligand for P-selectin, P-selectin glycoprotein
ligand-1 (PSGL-1), is expressed on subsets of activated ef-
fector T cells and is believed to be essential for the move-
ment of CD4- positive T cells into inflamed tissues [11].
Nonetheless, the extent to which selectins regulate the
movement of leucocytes to visceral organs and the contri-
bution of selectins to the regulation of chronic type 2 cyto-
kine dependent liver disease remain relatively unclear.
Consequently, this study aimed to assess the potential
expression of certain lymphocytes and platelets activation
molecules in chronic HCV and/or schistosomiasis mansoni
infections and their possible roles in progression of CLD.
Methods
Ethical approval
This study was conducted in compliance with the
Helsinki Declaration and was approved by ethical com-
mittee of Faculty of Medicine, Cairo University. (Archiv-
ing number; 15/2013).Written informed consents were
obtained from all participants.
Subjects
Eighty seven patients in addition to twenty healthy
subjects were selected from the Internal Medicine
Department, Kasr AL-Aini Faculty of Medicine, Cairo
University during the period from May 2013 to December
2013. The study population was divided into 5 groups.
Group-I: 21 patients with hepatic schistosomiasis as
evidenced by positive serology and portal tract thicken-
ing (grades I-III) by ultrasonography (14 males and 7
females). Group-II: 18 patients with chronic HCV infection
without cirrhosis (10 males and 8 females). Group-III: 23patients with concomitant hepatic schistosomiasis mansoni
and chronic HCV infections without cirrhosis (17 males
and 6 females). Group-IV: 25 patients with chronic HCV
and liver cirrhosis (14males and 11females). Group-V: 20
healthy individuals as controls (12 males and 8 females).
Exclusion criteria
Patients with hepatitis B virus (HBV), malignancy in-
cluding hepatocellular carcinoma (HCC) or renal, car-
diopulmonary or autoimmune disorders and pregnant
women were excluded from the study.
Methods
All participants in the current study were subjected to full
history taking (including contact with canal water) and clin-
ical examination in addition to the following investigations:
Abdominal ultrasound
To assess the hepatic physical condition including the grad-
ing of portal tract thickening in schistosomiasis mansoni
positive patients and the extent of liver cirrhosis.
Laboratory investigations
1. Complete Blood Count (CBC): Was measured by
Sysmix K-21 automatic cell counter (Japan).
2. Liver function tests: Serum levels of aspartate
transaminase (AST), alanine transaminase (ALT),
albumin, total and direct bilirubin were done
using Integra-400 (Roche-Germany). Prothrombin
concentration was estimated using Fibrintimer
(Roche- Germany).
3. Serological Screening for HBV & HCV: HBV
markers and HCV antibodies were assayed by EIA
(COBAS-Amplicore, Germany).
4. Qualitative assessment of HCV-RNA by PCR using
a commercial kit (Roche Diagnostic, Branchburg,
NJ) according to the manufacturer's instructions.
5. Diagnosis of Schistosomiasis mansoni: Direct wet
mount stool slides were examined in saline and
iodine preparations. Concentration slides were
prepared using formal-ether concentration
technique (FECT) with physiological saline and
examined [12]. ELISA sero-immunological detection
of anti-Schistosoma IgG antibodies was done by
indirect ELISA technique [13] using a specific
detection kit (Sigma, St. Louis, MO, USA) where
microtitration plates were sensitized using S.mansoni
soluble egg antigen according to the manufacturer's
recommendations. In addition, sera of all subjects
were screened for S. mansoni circulating antigen
using sandwich ELISA technique as described
previously [14]. All experiments were performed in
triplicate and data represent mean values. The
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value of the negative controls plus three standard
deviations. A sample was considered positive when
the absorbance of the three measurements was
greater than 0.114.
6. Flow-Cytometeric Analysis: For immunological
parameters, platelets rich plasma (PRP) was
separated and freshly tested using fluorescein
isothiocyanate (FITC) and phycoerythrin (PE)
conjugated monoclonal antibodies (moAbs) (BD
Biosciences. Com, Pharmingen TM). EDTA blood
was labeled with 10 μl specific moAbs in 3 tubes.
The first tube, for T-cell, contained CD3-peridin
chlorophyll protein (PerCP), CD4–fluorescein
isothiocyanate (FITC) and CD8-phycoerythrin (PE).
The second tube, for NK-cells, contained CD16/
CD56-PE and CD3-FITC. The third tube, for
B-cells, contained CD19-FITC and CD22-PE (all
Becton Dickson, San Jose, Calif ). A non-specific
isotype control was used in each sample. All
antibodies were of IgG1k isotype. Flow cytometer
Epics® Elite ʻʻCoulterʼʼ system was used for
analysis. Results were expressed as a specific
percentage of positive markers, calculated by
subtracting the non-specific fluorescence of the
isotype control from the specific fluorescence of the
moAbs [15]. For estimation of platelets activation,
250 μl EDTA blood was diluted and mixed 1:1 in
Hepes-buffer. Thrombin receptor activating peptide
(TRAP) (Bachem, Germany) was added at a final
concentration of 5 μm and samples were incubated
for 10 min at room temperature and fixed with one
volume 1% formaldehyde. A further inactivated
sample was kept for estimation of the baseline
fluorescence intensity. At the end of the activation
period 30 μl of fixed platelets were washed with
Hepes-buffer by centrifugation for 5 min at 750 g.
Platelet sediment was resuspended in 200 μl
Hepes-buffer and incubated with 10 μl FITC-anti-
CD62P (CD62P-FITC, DAKO, USA) and 10 μl
PE-anti CD42b antibody (CD42b-PE, DAKO, USA)
in darkness at room temperature for 30 min.
Sediment labeled platelets were analyzed in a
FAC-Scan cytometer (Becton Dickinson, USA).
Acquisition and processing of data from 5000
platelets were carried out with CONSORT software.
Binding of FITC-labeled antibodies to the surface
of stimulated platelets (CD42b positive) is used
for expression of CD62P in the form of mean
fluorescence intensity (MFI).
Statistical analysis
The data was coded and entered using the statistical
package SPSS version 15. The data was summarizedusing descriptive statistics: mean and standard deviation.
Statistical differences between groups were tested using
Chi-Square test for qualitative variables, independent sam-
ple t-test with multiple comparisons post-hoc for quantita-
tive normally distributed variables and nonparametric
Mann–Whitney test and Kruskal–Wallis test for not nor-
mally distributed quantitative variables. Two-way ANOVA
test was used to compare between variance of each marker
levels among four different infected groups and the
controls and P value <0.05 is considered significant.
Results
In the present study, subjects were divided into 5 groups.
Group-I: Twenty one patients with schistosomiasis mansoni
(14 males, 7 females) (mean age 48.4 ± 3.9 year). Group-II:
Eighteen patients with HCV infection (10 males, 8 females)
(mean age 52.4 ± 4 year). Group-III: Twenty three patients
with concomitant schistosomiasis mansoni and HCV infec-
tions (17 males, 6 females) (mean age 56.5 ± 2.7 year).
Group-IV: Twenty five patients with chronic HCV and cir-
rhosis (14males and 11females) (mean age 58 ± 5.76 year)
and group-V: Twenty healthy controls (12 males and 8 fe-
males) (mean age 46.8 ± 2.5 year). Haematological findings
revealed a significant thrombocytopenia in all infected
groups in comparison to the control one (P < 0.05) with in-
significant (P > 0.05) low Hb concentrations and WBC
counts (Table 1). Immunologically, there is a significant
reduction in the total T-cells (CD3+%) in all infected groups
(P < 0.05) compared to the control group. In addition, a
significant reduction in the percentage of the Th-cells
(CD4+%) was observed in all infected groups (P < 0.05). On
the other hand, the percentage of Tc-cells (CD8+%) was
higher in all infected groups (P < 0.05) as shown in Table 2.
Regarding B and NK cells, a significant increase in CD19,
CD22 (B-cell markers) and CD56 (NK-cell marker) in
all infected groups (P < 0.05) compared to the control group
(Table 2). The platelet count was significantly decreased
(P < 0.05) in all infected groups that was more evident
in group-IV (Table 3). The percentages of CD41 and
CD42 platelet activation markers were reduced in all in-
fected groups compared to the control group, however,
these values were statistically significant in group III &
IV (for CD41) and in group II, III & IV (for CD42).
The positivity of CD62P (P-selectin) was 12.5 ± 1.9 in the
control group while the values were 28.9 ± 4.3, 48 ± 5.2,
67.6 ± 4.4 and 73.4 ± 6.1 in group I, II, III &IV respectively
(P < 0.05) with significant increased platelet activation that
was mostly significant in group-IV followed by group-III.
The MFI in group I, II, III and IV were 12.8 ± 1.4, 15.5 ±
2.5, 17.8 ± 2 & 22.2 ± 1.6 respectively. All were significantly
higher (P < 0.05) than the control group (5.9 ± 0.3) (Table 3).
The correlation between platelet count and platelet activa-
tion revealed an inverse correlation (r = −0.79) (P < 0.05) of
the platelet count and the CD62P%. The platelet count was
Table 1 Age and laboratory findings of different groups
Group I (Schistosomiasis) Group II (HCV) Group III (Schist. & HCV) Group IV (HCV with cirrhosis) Group V (Controls)
Age 48.4±3.932 52.0±4.027 56.5±2.68 58±5.76 46.8±2.458
Total bilirubin 0.67±0.22 1.2±0.44 1.1±0.56 2.1±1.7 0.58±0.32
ALT 30±2.4 51±6.7 49±7.1 35±4.9 27±5.4
AST 29±6.5 37±9.6 38±4.5 39±5.2 25±7.8
PC 89.3±2.1 87.2±3.6 85±4.2 51.3±7.3 96.2±1.6
Albumin 4.2±1.1 3.8±1.7 3.9±1.3 2.8±1.2 4.8±1.1
Hb 11.3±0.5 11.5±0.5 11.2±0.5 10.5±0.7 12.8±1.1
WBC 7381±694 6090±521 5550±567 3250±1650 7500±744
Platelet count 161±9,3 135±1,5 134±9,6 112±2,5 275±20
Neutrophils% 48.4±2.9 50.9±2.3 51.7±2.3 52.1±4.1 53.1±2.7
Lymphocytes% 38.2±3.1 34.3±3.1 36.3±2.1 37.5±2.6 33.3±2.6
Monocytes% 8.7±0.8 10.5±1.4 7.9±0.4 10.0±1.9 8.2±0.7
Values are expressed as mean ± SD.
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flowcytomtery (r =− 0.74) (P < 0.05) (Figure 1 and Figure 2).
Discussion
This study aimed to characterize the expression of plate-
lets and lymphocytes activation molecules in CLD in dis-
tinct or simultaneous chronic HCV and schistosomiasis
mansoni infections. Patients with CLD are suffering
from impairment of immune function due to significant
reduction of both CD3+ and CD4+ lymphocytes. This
reduction was found to be correlated with severity of
liver disease [16].
In agreement with that, the current study revealed a
significant decrease in CD3+ and CD4+ cells in HCV, S.
mansoni infected groups, concurrent dually infected
individuals and those with liver cirrhosis. These findings
agreed with the fact that, the absence of an adequate
CD4 + cell response is associated with incomplete HCV
eradication by memory CD8+ cells and failure to resolve
HCV infection [17]. Additionally, low CD4 + cells counts
are also associated with increased rates of liver fibrosisTable 2 Immunological profiles of different groups
CD %
Group I Group II Group III Group IV Group V
CD3 48.2±1.9b 53.7±1.7b 48.7±1.3b 44.7±3.1b 63.8±1.3a
CD4 25.7±1.2b 27.0±1.5b 25.5±1.4b 24.5±1.8b 42.9±0.9a
CD8 26.3±1.3a 25.8±1.6a 25.2±0.8a 24.5±1.4a 20.2±0.7b
CD19 17.2±0.9a 18.4±1.3a 17.7±0.7a 18.1±1.1a 14.3±1.0b
CD22 16.5±0.9a 17.9±1.1a 17.4±0.6a 18.7±0.9a 13.8±0.8b
CD56 12.8±0.7a 13.6±1a 14.9±0.5a 15.2±0.7a 9.7±0.6b
Values are expressed as mean ± SE.
Statistically significant values (P<0.05).
Means followed by the same superscript letter within the same row means
non-significant variation (P>0.05) in relation to each other, but statistically
significant in relation to the control group.[18]. Recently, data show that HCV-core protein induces
a suppressor phenotype in CD4+ T-cells. HCV-core
expressing CD4+ T-cells showed an anergic phenotype,
being unresponsive to T-cell receptor (TCR) stimulation
and being able to suppress polyclonal CD4+ and CD8+
T-cell activation [19].
In a bit similar mechanism, S. mansoni appeared to
utilize the activities of CD4+ T-cells to assist the parasite
development and fecundity [20]. This was explained
by Kullberg and his colleagues who mentioned that
S. mansoni implied a Th2-cytokine-mediated immuno-
pathogenesis with impairment of the Th1-dependent
immune response involving both CD4 + T-cell delayed-
type hypersensitivity responses and CD8+ T-cell anti-
viral effector functions [21].
In the present study, we reported an increase in the
percentage of Tc-cells (CD8+) in all infected groups.
This was confirmed by Manfras et al. who stated that
the increased oligoclonality of CD8+ lymphocytes is
associated with increased fibrosis and reduced responses
to antiviral therapy [22]. On the same line, Li et al.
found that the ratio of CD4+/CD8+ was significantly
decreased in Schisotosoma-infected patients and those
with parenchymal fibrosis [23].
Also, our study revealed a significant increase in the
B-cell markers (CD19& CD22) observed in patients with
HCV infection. These results are consistent with previ-
ous studies which explained that HCV can replicate in
CD19+ B-cells [24] as HCV envelope protein-E2 binds
the CD81 molecule that is expressed on hepatocytes and
various cell types including B-cells [25]. Moreover, recent
evidence reported that at least one HCV replication
marker was found in 50% and 30.8% of CD3+ and CD19+
cells respectively. The authors added that the highest
percentage of cells harboring the viral markers in a single
specimen was observed in CD3+ (2.4%), then in CD19+
Table 3 Platelet counts, markers and activation in different groups
Group I Group II Group III Group IV Group V
Platelet count 161±9,3b 135±1,5c 134±9,6c 112±2,5d 275±20a
CD62% 28.9±4.3d 48.0±5.2c 67.6±4.4b 73.4±6.1a 12.5±1.9e
MFI 12.8±1.4c 15.5±2.5b 17.76±2.0b 22.2±1.6a 5.9±0.25d
CD41% 91.9±0.6ab 91.9±0.8ab 90.4±1.1b 87.4±4.0b 94.1±0.7a
CD42% 92.2±0.7ab 91.5±0.7b 91.1±0.9b 90.2±1.5b 94.7±0.6a
Values are expressed as mean ± SE.
Statistically significant values (P<0.05).
Means followed by the same superscript letter (a,b,c,d or e) within the same row means non-significant variation (P>0.05) in relation to each other, but statistically
significant in relation to the other groups and to the control group.
Mean followed by (ab) superscript means that this group is statistically insignificant to either groups with superscript (a) and superscript (b).
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of persistent stimulation of B-cells by viral antigens that
could be responsible for polyclonal and later to monoclo-
nal expansion of B-cells [27,28]. Nevertheless, B-cells
cannot support HCV replication in certain HCV strains
but can bind HCV and trans-infect hepatocytes [29].
In schistosomiasis, it was reported that the mean
percentage of circulating CD19+ B-cells was significantly
high in S. mansoni–infected patients [30]. This could be
explained through studies carried on schistosomiasis
mansoni-infected B cell-deficient mice, which revealed
more extensive hepatic granulomas that were explained
by the role of B-cells in the down modulation of liver
pathology through promoting Th2-type responses [31,32].
In addition to CD19, we reported that CD22 was highly
expressed in HCV& cirrhotic patients. CD22 is known
as an inhibitory receptor specifically expressed on
B-lymphocytes. Eosinophils are known to express the
receptor for IL-4, which induce CD22 on B-cells. CD22
is functionally involved in regulating GI eosinophil levels
[33]. To our knowledge, the current study is one of the
earliest reports demonstrating high expression of the pan










Figure 1 Correlation between platelet count and CD62P%.In the present study, we revealed that patients with
chronic HCV showed an increase in CD56+ NK-cells in
their peripheral blood. What is more is that, the percent-
age of NK-cells (CD56%) showed a significant increase
in all infected groups. These results are adding to the
several arguments about the alterations of the peripheral
NK-cells for patients chronically infected with HCV.
First, previous studies have shown that chronic HCV in-
fection is allied with diminished NK-cell frequency and
function in the peripheral blood and in the liver [34].
Moreover, Golden-Mason et al. reported that the reduc-
tion in CD56+ NK levels occurred early in acute HCV
infection and did not fluctuate over time [35]. On the
other hand, two earlier reports did not detect any decre-
ment in peripheral blood NK-cell percentages in HCV
infection [36,37]. Furthermore, another study revealed
no observed differences between chronic HCV patients
and healthy individuals in the number and frequencies
of CD56 NK-cells [38]. We proposed a potential elucida-
tion for these variations which could be selective trap-
ping of CD56 NK-cells in the liver in case of HCV
infection resulting in alterations of the tissue localization
of these cells. Despite this suggestion, there is no strongr= -0.79
p<0.05
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Figure 2 Correlation between platelet count and MFI.
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infection as the ratios of CD56- subsets in blood and
liver of HCV patients were very similar [39].
Similarly in schistosomiasis infection, the large numbers of
NK-cells induces inhibition of Schistosoma development [40].
Patients with advanced liver diseases have a complex
hemostatic disturbance and thrombocytopenia [41].
Thrombocytopenia and platelet function abnormalities
are commonly found in patients with CLD [42]. In agree-
ment with that the current study revealed significant
thrombocytopenia in all infected groups.
Platelets facilitate T-cell adhesion and may influence
other functional aspects of T-cells by releasing platelet-
factor-4 (PF4) that regulates multiple T-cell activities
[43]. It was shown that platelet depletion diminished
accumulation of virus specific Tc-lymphocytes and mini-
mized organ damage. On the other hand, platelets seem
to enhance the generation of IFN-γ- producing TC-cells
[44]. Accordingly, the effect of thrombocytopenia on
CLD progression among HCV and/or Schistosom- in-
fected patients might be exerted through alterations in
T-cell functions and activity.
Additionally, platelets have a role in protection against
schistosomiasis through expression of IgE-receptors
that are considered as an important defense mechanism
in parasitic infection [45]. IgE binding induces platelet
release of cytotoxic mediators that subsequently kill
Schistosoma [41]. Even though IgE is known to be pro-
tective against adult stages of S mansoni; studies during
the chronic stage of infection reported that IgE anti-
parasite antibodies have been implicated as protective
against the soluble egg antigens (SEA), as it was re-
ported that SEA-IgE antibody level was associated with
resistance to reinfection with S. japonicum [46].
Similarly, IgE-isotypes to SEA, in 58 patients from
Brazil were analyzed, in order to evaluate the patterns of
antibodies responses before and after treatment. Beforetreatment, IgE and IgG4-anti-SEA antibody levels were
more elevated. These antibody levels tended to increase
after treatment suggesting stimulation of the antibody
response owing to the drug effects or antigens exposure
due to parasitic stage damage [47].
Chronic HCV infection induces alterations of markers of
inflammation and endothelial dysfunction [48]. In addition,
the increased level of P-selectin has been proposed as a
marker of in-vivo platelet activation [49]. Although, a
significant positive relationship was reported between an
increased serum P-selectin during anti-HCV therapy [48],
the current study detected an increase in the positivity of
the CD62P (P-selectin) demonstrating an increased platelet
activation that was significantly observed in group-IV
followed by group-III, group-II then group-I. Such increase
in P-selectin in the cirrhotic group compared to the
non-cirrhotic and control groups may propose the role of
P-selectin in progression of CLD.
The MFI in all infected groups was significantly higher
(P < 0.05) than that of the control group (5.9 ± 0.3). An
inverse correlations between the platelet count and MFI
(r = −0.74) were observed. MFI rate is a numerical data
reflecting the severity of antigen expression [42]. These
findings were in agreement with a study reported that
plasma soluble P-selectin levels were markedly elevated
in chronic HCV which correlated directly with serum
HCV-RNA and was significantly higher in patients with
low platelet counts [50]. Moreover, Panasiuk et al., found
elevated P-selectin expression in chronic hepatitis and
cirrhosis and they suggested that HCV infection might
be directly responsible for the in-vivo platelet activation
in patients with chronic HCV [16]. On contrary, Wynn
et al. concluded that P-selectin exhibits critical anti-
inflammatory and anti-fibrotic activity and dramatically
inhibit the pathologic tissue remodeling resulted from
chronic type-2 cytokine-mediated inflammation [10].
This was ascertained by Laschke et al. who reported that
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was reported to decrease aggregate formation, platelet
adhesion and leukocyte accumulation resulting in im-
proved liver functions [43].
During experimental schistosomiasis, the presence of
lacto-N-fucopentaose-III (LNFP-III) was demonstrated
on SEAs [51]. LNFP-III induces proliferation of splenic
B-lymphocytes of S.mansoni-infected mice to produce
IL-10 and thus down-modulate Th1. Interaction between
LNFP-III and B-lymphocytes is mediated by P-selectin
[52]. In addition, it was found that P-selectin, acts as a
decoy-receptor up-regulating IL-13Rα2 in S. mansoni in-
fection [10] with subsequent exacerbation of S. mansoni
associated liver fibrosis due to increased IL-13activity
[53]. Also, Liu and his colleagues reported that markedly
elevated protein expression of IL-13 was detected in pa-
tients with HCV-associated cirrhosis which could eluci-
date the elevated P-selectins in patients with HCV [54].
In the current study, all groups exhibited decreased
expression of CD41 and CD42 which are known to be
expressed on the surface of resting and activated plate-
lets. These results could be explained by the hypothesis
that platelets microvesicles (PMVs) may transfer specific
platelets antigen CD41/CD61 into other cells reducing
their expression on activated platelets [55]. Moreover,
in case of diseases with immunological disturbances,
platelets may serve as targets for anti-platelet antibodies
targeting the micromolecules expressed on their sur-
faces [55,56]. To a certain extent, similar results were
reported in a flow cytometric assay for immunopheno-
typing of PMVs in platelet rich plasma concentration
in two groups of patients with and without inflamma-
tion. In both studied groups after thrombin stimula-
tion the number of PMVs was decreased, however,
the platelets delivered more PMVs expressing activa-
tion marker CD62P. The number of PMVs expressing
CD41+ CD62P + was only increased in patients with-
out signs of inflammation [56].
Conclusion
The present study highlights the considerable role of
P-selectin in the progression of CLD caused by HCV and
S.mansoni. By upregulating platelet activation, P-selectin
modulates consequences of chronic type 2 cytokine–
mediated inflammation. Although selectins frequently
are referred to as provocative mediators, it remains
indistinct whether this impact results from the direct
effect of P-selectin on leukocyte recruitment or it is
basically an outcome of the altered host immune reac-
tion. The extent of platelet and lymphocyte activation
markers described herein releases a new gap for prog-
nostics predicting the progression of HCV and schisto-
somiasis mansoni induced CLD and consequently, the
development of new preventive measures.Abbreviations
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